Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 5 years of Non-Current Deffered Revenue data on record, last reported at $140000.0 in Q2 2025.

  • For Q2 2025, Non-Current Deffered Revenue fell 67.29% year-over-year to $140000.0; the TTM value through Jun 2025 reached $140000.0, down 67.29%, while the annual FY2024 figure was $284000.0, 50.44% down from the prior year.
  • Non-Current Deffered Revenue reached $140000.0 in Q2 2025 per VRDN's latest filing, down from $212000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q4 2021 and bottomed at $140000.0 in Q2 2025.
  • Average Non-Current Deffered Revenue over 5 years is $644600.0, with a median of $645000.0 recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 25.07% in 2022, then crashed 67.29% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.1 million in 2021, then decreased by 25.07% to $861000.0 in 2022, then crashed by 33.45% to $573000.0 in 2023, then crashed by 50.44% to $284000.0 in 2024, then crashed by 50.7% to $140000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $140000.0 in Q2 2025, $212000.0 in Q1 2025, and $284000.0 in Q4 2024.